Dermata Therapeutics Warrant
DRMAW
3 hedge funds and large institutions have $20.9K invested in Dermata Therapeutics Warrant in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.
17% more capital invested
Capital invested by funds: $17.9K → $20.9K (+$3.03K)
2.02% more ownership
Funds ownership: 0.59% → 2.61% (+2%)
40% less funds holding
Funds holding: 5 → 3 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$195 |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$36 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
1
Boothbay Fund Management
New York
| $19.8K | – | – | – |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $575 | -$195 | -8,069 | -21% |
|
|
AC
3
Armistice Capital
New York
| $508 | – | -1 | -0% |
|
|
4
UBS Group
Zurich,
Switzerland
| – | -$36 | -1,800 | Closed |
|
|
5
Bank of America
Charlotte,
North Carolina
| – | -$2 | -100 | Closed |
|
DRMAW Hedge Fund Activity: Q2 2023 in Review
3 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q2 2023, worth a combined $20.9K — up 17% from $17.9K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of DRMAW and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Warberg Asset Management, cutting an estimated $195.
- 3 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q2 2023, down from 5 in Q1 2023.
- Funds reported $20.9K of Dermata Therapeutics Warrant stock for Q2 2023, up 17% quarter-over-quarter.
- 0 funds opened new Dermata Therapeutics Warrant positions in Q2 2023 and 2 closed out, a net change of -2 holders.
- The largest Dermata Therapeutics Warrant seller in Q2 2023 was Warberg Asset Management, an estimated $195 sold.
Based on aggregated 13F filings for Q2 2023.